Format

Send to

Choose Destination
Oncotarget. 2016 May 24;7(21):31586-601. doi: 10.18632/oncotarget.8040.

FAK and paxillin, two potential targets in pancreatic cancer.

Author information

1
Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA.
2
Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA.
3
Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA, USA.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a devastating cancer in large part due to late diagnosis and a lack of effective screening tests. In spite of recent progress in imaging, surgery and new therapeutic options for pancreatic cancer, the overall five-year survival still remains unacceptably low. Numerous studies have shown that focal adhesion kinase (FAK) is activated in many cancers including PDAC and promotes cancer progression and metastasis. Paxillin, an intracellular adaptor protein that plays a key role in cytoskeletal organization, connects integrins to FAK and plays a key role in assembly and disassembly of focal adhesions. Here, we have reviewed evidence in support of FAK as a potential therapeutic target and summarized related combinatorial therapies.

KEYWORDS:

FAK; P53; integrins; pancreatic cancer; paxillin

PMID:
26980710
PMCID:
PMC5058780
DOI:
10.18632/oncotarget.8040
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center